NASDAQ:ZYBT Zhengye Biotechnology (ZYBT) Stock Price, News & Analysis $1.54 +0.05 (+3.36%) Closing price 04:00 PM EasternExtended Trading$1.54 -0.01 (-0.32%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC Filings About Zhengye Biotechnology Stock (NASDAQ:ZYBT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Zhengye Biotechnology alerts:Sign Up Key Stats Today's Range$1.45▼$1.5550-Day Range$1.11▼$1.7352-Week Range$0.62▼$8.01Volume15,028 shsAverage Volume84,557 shsMarket Capitalization$72.98 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Zhengye Biotechnology Group Co., Ltd. is a China-based biotechnology company focused on developing, manufacturing and selling biological products for the agricultural and animal husbandry industries. Its business is centered on applying microbial technologies to support animal health, livestock production and crop cultivation. The company’s product offerings include microbial-based products used in animal feed and agricultural production, as well as related biological solutions intended to improve farming efficiency and promote healthier livestock and crops. Its products are marketed primarily to customers in China’s agriculture and animal husbandry sectors. Zhengye Biotechnology is headquartered in China and operates through research, production and sales activities serving the domestic market. Publicly available information about its operating history and leadership is limited, and the company’s business remains focused on biotechnology applications for agriculture and animal health.AI Generated. May Contain Errors. Read More Zhengye Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks10th Percentile Overall ScoreZYBT MarketRank™: 0.49834327369 of 5 starsZhengye Biotechnology scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingZhengye Biotechnology has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageZhengye Biotechnology has only been the subject of 1 research reports in the past 90 days.Read more about Zhengye Biotechnology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioZhengye Biotechnology has a P/B Ratio of 1.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.07% of the float of Zhengye Biotechnology has been sold short.Short Interest Ratio / Days to CoverZhengye Biotechnology has a short interest ratio ("days to cover") of 0.44, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Zhengye Biotechnology has recently decreased by 53.89%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldZhengye Biotechnology does not currently pay a dividend.Dividend GrowthZhengye Biotechnology does not have a long track record of dividend growth. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Zhengye Biotechnology this week, compared to 2 articles on an average week. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Zhengye Biotechnology insiders have not sold or bought any company stock.Percentage Held by InstitutionsZhengye Biotechnology has minimal institutional ownership at this time.Read more about Zhengye Biotechnology's insider trading history. Receive ZYBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zhengye Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZYBT Stock News HeadlinesZhengye Biotechnology Holding Ltd (ZYBT)August 28, 2026 | ru.investing.comZhengye Biotechnology Regains Nasdaq Minimum Bid Price ComplianceAugust 6, 2026 | tipranks.comEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.November 10 at 1:00 AM | Behind the Markets (Ad)Why Zhengye Biotechnology Holding (ZYBT) Stock Is Up TodayAugust 5, 2026 | quiverquant.comQZhengye Biotechnology Stock Short Interest Report | NASDAQ:ZYBT | BenzingaJuly 23, 2026 | benzinga.comZhengye Biotechnology Addresses Unusual Nasdaq Trading ActivityJuly 21, 2026 | tipranks.comZhengye Biotechnology says no material events behind unusual trading activity (NASDAQ: ZYBT)July 21, 2026 | msn.comZhengye Biotechnology Holding Limited Says It Is Unaware of Material Non-Public Information Amid Unusual Trading ActivityJuly 21, 2026 | quiverquant.comQSee More Headlines ZYBT Stock Analysis - Frequently Asked Questions How have ZYBT shares performed this year? Zhengye Biotechnology's stock was trading at $1.15 at the beginning of 2026. Since then, ZYBT shares have increased by 33.9% and is now trading at $1.54. When did Zhengye Biotechnology IPO? Zhengye Biotechnology (ZYBT) raised $6 million in an IPO on Tuesday, January 7th 2025. The company issued 1,500,000 shares at $4.00 per share. Kingswood Capital Partners served as the underwriter for the IPO. How do I buy shares of Zhengye Biotechnology? Shares of ZYBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ZYBT's financial health is in the Yellow zone, according to TradeSmith. ZYBT has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ZYBT Previous SymbolNASDAQ:ZYBT CIK1975641 Webwww.jlzybio.com Phone86-13844801919FaxN/AEmployees269Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$16.64 million Price / Sales4.39 Cash FlowN/A Price / Cash FlowN/A Book Value$0.93 per share Price / Book1.66Miscellaneous Outstanding Shares47,390,000Free FloatN/AMarket Cap$72.98 million OptionableN/A Beta-2.33 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:ZYBT) was last updated on 11/10/2026 by MarketBeat.com Staff. From Our PartnersBlack Friday Bombshell (for traders)For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredIntel Shares Jumped 177% After Elon Musk's DealElon Musk's April 2026 partnership with Intel sent shares climbing 177% within two months. Jeff Brown, the ...Brownstone Research | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zhengye Biotechnology Holding Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Zhengye Biotechnology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
